Yahoo · Sep 25, 2026
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
AN
NASDAQ · ANIK
Anika Therapeutics, Inc.
Healthcare · Medical - Devices
$19.23
Down-$0.30 (-1.54%)
Updated Oct 9, 2026, 3:32 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 207.09M
- P/E ratio
- -18.84
- Dividend yield
- 0.00%
- 52-week range
- $8.67 – $22.88
- Volume
- 126.5K
- Avg. volume
- 156.61K
Price performance · ANIK
ANIK price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
ANIK closed at $19.23 after 21 trading sessions, down 8.38% for the selected period.
- Last close
- $19.23
- Period change
- -8.38%
- Period low
- $19.10
- Period high
- $21.19
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $19.39 | $19.39 | $18.90 | $19.23 | 126.5K |
| Oct 7, 2026 | $19.01 | $19.63 | $18.11 | $19.53 | 182.65K |
| Oct 6, 2026 | $19.73 | $19.80 | $19.05 | $19.12 | 64.74K |
| Oct 5, 2026 | $19.18 | $19.88 | $19.07 | $19.73 | 122.28K |
| Oct 2, 2026 | $19.41 | $19.47 | $19.01 | $19.10 | 92.26K |
| Oct 1, 2026 | $19.55 | $19.9699 | $19.09 | $19.36 | 111.91K |
| Sep 30, 2026 | $19.93 | $20.41 | $19.64 | $19.66 | 72.12K |
| Sep 29, 2026 | $20.67 | $20.67 | $19.64 | $19.945 | 151.38K |
| Sep 28, 2026 | $20.72 | $20.94 | $20.37 | $20.68 | 145.02K |
| Sep 25, 2026 | $20.23 | $20.82 | $20.1301 | $20.37 | 58.16K |
| Sep 24, 2026 | $20.26 | $20.635 | $20.00 | $20.23 | 87.98K |
| Sep 23, 2026 | $20.71 | $20.71 | $20.22 | $20.375 | 61.98K |
| Sep 22, 2026 | $20.92 | $21.0499 | $20.595 | $20.89 | 45.27K |
| Sep 21, 2026 | $20.81 | $21.1421 | $20.45 | $20.70 | 83.52K |
| Sep 18, 2026 | $21.03 | $21.05 | $20.545 | $20.81 | 118.47K |
| Sep 17, 2026 | $21.04 | $21.32 | $20.89 | $21.03 | 47.7K |
| Sep 16, 2026 | $20.79 | $21.16 | $20.755 | $20.84 | 50.58K |
| Sep 15, 2026 | $21.19 | $21.19 | $20.635 | $20.91 | 81.74K |
| Sep 14, 2026 | $20.86 | $21.38 | $20.81 | $21.19 | 49.57K |
| Sep 11, 2026 | $21.25 | $21.29 | $20.73 | $20.86 | 70.32K |
| Sep 10, 2026 | $20.88 | $20.99 | $20.575 | $20.99 | 48.41K |
Latest ANIK news
The latest Smart Investors Daily articles mentioning ANIK.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ANIK research
Overview
Company profile and research snapshot.
Company profile
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | B. Riley Securities | Buy | — |
| Feb 27, 2026 | Barrington Research | Outperform | — |
| Jan 9, 2026 | Barrington Research | Outperform | — |
| Nov 6, 2025 | Barrington Research | Outperform | — |
| Sep 23, 2025 | Barrington Research | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 25, 2026
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Yahoo · Sep 18, 2026
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
Benzinga · Sep 18, 2026
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23
B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics (NASDAQ:ANIK) with a Buy rating and raises Price Target to $23.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
